TP53 and neoplasm: In addition, the significantly shorter tumor latency in these rats compared to that in rats injected with either AAV-N or AAV-T (p<0.01) demonstrates an oncogenic collaboration between these Nf1 and Tp53 mutations in driving breast tumorigenesis.